The World Health Organization told the world's doctors on October 7 to keep weight-loss drugs away from children under 10. In teenagers the drugs should be a last resort, reached for only after a supervised lifestyle program has already failed. It is the first time the agency has issued global guidance ↗ on obesity in children and adolescents, and it lands in the middle of a GLP-1 prescribing boom.
The guidance comes in two documents, one for children ↗ under age 10 and one for adolescents ↗ aged 10 to 19. For the younger group the WHO makes what it calls a strong recommendation against obesity medicines, bariatric surgery, and weight-loss devices, and tells clinicians to use diet, physical activity, and behavioral support instead. "Strong" is the agency's firmest category, and here it rests on low-quality evidence, meaning few trials and short ones rather than clear proof of harm.
For adolescents the door is open but narrow. Medicines may be considered only for teens who already have obesity-related complications, such as type 2 diabetes or uncontrolled high blood pressure. Even then, the bar is a supervised program of diet, exercise, and behavior change lasting at least six months that has not worked. Treatment is meant to come from a specialist team with long-term follow-up, not a single prescription. Bariatric surgery sits behind an even higher bar, reserved for severe cases under strict conditions.
The drugs in question are the ones driving the adult obesity market. Semaglutide ↗, sold as Wegovy, and liraglutide ↗, sold as Saxenda, are the GLP-1 injections with pediatric obesity approvals in the US and Europe, both cleared down to age 12. Orlistat, an older fat-blocking pill, is the other medicine the WHO reviewed. All three act on obesity. But the GLP-1 drugs mimic a gut hormone that signals fullness through the GLP-1 receptor ↗, and that is why the pediatric question is urgent rather than academic.
The WHO's evidence review found most pediatric trials were short, and it noted that teenagers taking GLP-1 drugs or orlistat stopped more often because of side effects. That is the quiet center of the guidance. The agency is not saying the drugs fail to work in young people. It is saying the long-term safety record in bodies that are still developing does not yet exist, and that a six-month behavioral program is the thing to try first.
This puts the WHO somewhat more cautious than the United States. The American Academy of Pediatrics drew criticism in 2023 for guidance that many read as endorsing drugs and surgery earlier in the course of childhood obesity. The WHO's framing is closer to stepped care: lifestyle first for everyone, drugs as a conditional second step for teens with complications, surgery last. For a global agency whose recommendations shape national drug formularies and insurance rules far beyond wealthy countries, where the line sits matters.
None of this changes an adult prescription. But it draws a public, global marker at age 10 for a drug class that has spent two years expanding into every adjacent indication. The companies behind Wegovy and its rivals ran pediatric trials precisely because the market there is large. The WHO just told them the burden of proof for treating children is higher than the burden for treating adults, and that lifestyle support, not a weekly shot, is where treatment for a 9-year-old starts.